Premium
Occludin‐binding single‐chain variable fragment and antigen‐binding fragment antibodies prevent hepatitis C virus infection
Author(s) -
Shimizu Yoshimi,
Shinoda Takehiro,
Shirasago Yoshitaka,
Kondoh Masuo,
Shinya Naoko,
Hanada Kentaro,
Yagi Kiyohito,
Suzuki Tetsuro,
Wakita Takaji,
KimuraSomeya Tomomi,
Shirouzu Mikako,
Fukasawa Masayoshi
Publication year - 2021
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1002/1873-3468.13975
Subject(s) - antibody , monoclonal antibody , single chain variable fragment , hepatitis c virus , occludin , antigen , virology , microbiology and biotechnology , chemistry , in vitro , biology , virus , immunology , tight junction , biochemistry
Occludin (OCLN) is a tetraspan membrane component of epithelial tight junctions and a known receptor for hepatitis C virus (HCV). Previously, we established functional monoclonal antibodies (mAbs) that bind to each extracellular loop of OCLN and showed their ability to prevent in vitro and in vivo HCV infection. In this study, we converted these mAbs to corresponding monovalent antigen‐binding fragments (Fabs) and single‐chain variable fragment (scFv) antibodies. These Fab fragments and scFv antibodies demonstrate similar binding specificity and affinity to parental anti‐OCLN mAbs. Moreover, Fab fragments and scFv antibodies inhibit in vitro HCV infection. The small functional monovalent OCLN‐binding probes reported in our study have high potential as drug candidates and tools for biological and pharmaceutical studies of OCLN.